Detailed mechanistic research is also needed to establish the relative contributions of G protein- and β-arrestin-mediated effects at both GLP-1R and GCGR and will help clarify how investigational incretin receptor agonists are prioritised during drug development for T2D and obesity. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.